Macrolide Antibiotics

Erythromycin is acid-labile, undergoing significant degradation in the stomach. Enteric-coated and ester formulations were developed to improve oral delivery, but bioavailability remains variable (approximately 35–65%). Its half-life of approximately 1.5–2 hours requires four-times-daily oral dosing. Erythromycin is a potent inhibitor of cytochrome P450 3A4 and is the most potent CYP3A4 inhibitor of the three major macrolides. The prokinetic effect of erythromycin (through motilin receptor agonism) has been exploited therapeutically at sub-antimicrobial doses for gastroparesis.

Clarithromycin is an acid-stable derivative of erythromycin with oral bioavailability of approximately 50–55% and a half-life of approximately 3–7 hours supporting twice-daily dosing. It is hepatically metabolized to an active 14-hydroxy metabolite that contributes to Haemophilus influenzae coverage. Clarithromycin is a significant cytochrome P450 3A4 inhibitor, intermediate in potency between erythromycin and azithromycin. Clinically important interactions include elevated simvastatin and lovastatin levels (myopathy risk), elevated colchicine levels (potentially fatal in renal impairment), increased warfarin effect, and elevated cyclosporine and tacrolimus concentrations in transplant recipients.

Oral bioavailability averages approximately 37%, but this figure is misleading: the drug is taken up avidly by cells crossing the gut wall and distributes into tissues before entering systemic circulation. Tissue concentrations reach 10 to 100 times concurrent serum levels, concentrated in alveolar macrophages, neutrophils, and monocytes. This produces a tissue half-life of approximately 68 hours, enabling once-daily dosing and short-course regimens (such as 5-day courses for respiratory infections or single-dose therapy for Chlamydia trachomatis urethritis). Because serum concentrations are substantially lower than tissue concentrations, azithromycin is unreliable for treating bacteremia.

Azithromycin produces negligible cytochrome P450 3A4 inhibition at clinical doses and is the preferred macrolide in patients taking cytochrome P450 3A4-sensitive medications. All three macrolides are eliminated primarily by hepatic metabolism and biliary excretion; azithromycin requires no dose adjustment for renal impairment.

Macrolides are first-line agents for outpatient community-acquired pneumonia in previously healthy adults without recent antibiotic use or risk factors for drug-resistant Streptococcus pneumoniae. Their activity against both typical respiratory pathogens and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) makes them suited for empiric monotherapy. Infectious Diseases Society of America and American Thoracic Society guidelines endorse macrolide monotherapy for outpatient community-acquired pneumonia in low-risk patients where macrolide resistance among pneumococcal isolates is below 25%. In higher-resistance regions, a respiratory fluoroquinolone is preferred. For hospitalized patients, a macrolide is combined with a beta-lactam to cover both typical and atypical organisms.

Azithromycin 1 gram as a single oral dose was the standard treatment for uncomplicated Chlamydia trachomatis infection for decades, exploiting its unique pharmacokinetics for sustained intracellular concentrations from a single dose. Updated Centers for Disease Control and Prevention guidelines now prefer doxycycline 100 mg twice daily for 7 days over single-dose azithromycin for uncomplicated chlamydia in non-pregnant patients, due to concerns about treatment failures and rising minimum inhibitory concentrations for Mycoplasma genitalium. Azithromycin remains preferred for chlamydia in pregnancy, where tetracyclines are contraindicated. Macrolides are no longer recommended as primary therapy for Neisseria gonorrhoeae due to widespread resistance.

Azithromycin is the preferred agent for pertussis (Bordetella pertussis) treatment and post-exposure prophylaxis, having displaced erythromycin due to superior tolerability and a shorter course. The standard regimen is azithromycin 500 mg on day 1 followed by 250 mg on days 2 through 5. Clarithromycin-based triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole) remains a standard regimen for Helicobacter pylori eradication, though clarithromycin resistance exceeding 15–20% in many regions has prompted bismuth quadruple therapy as an alternative.

Clarithromycin and azithromycin are the cornerstone agents for Mycobacterium avium complex treatment and prophylaxis. For prophylaxis in patients with human immunodeficiency virus infection and CD4 T-cell counts below 50 cells per microliter, azithromycin 1200 mg once weekly is the preferred regimen. For active Mycobacterium avium complex treatment, clarithromycin 500 mg twice daily combined with ethambutol (with or without rifabutin) is the recommended regimen; azithromycin is used as an alternative in patients who cannot tolerate clarithromycin or have significant drug interactions. Macrolide monotherapy for Mycobacterium avium complex is contraindicated because it rapidly selects for macrolide resistance through point mutations in the 23S ribosomal RNA gene.

The predominant macrolide resistance mechanism in gram-positive bacteria is the macrolide-lincosamide-streptogramin B resistance phenotype, encoded by erm genes. The erm methylase modifies the ribosomal binding site, reducing affinity for macrolides, lincosamides (clindamycin), and streptogramin B simultaneously. This resistance can be constitutive (always expressed) or inducible (expressed only when the organism is exposed to a macrolide inducer). Inducible resistance is clinically critical: organisms that test susceptible to clindamycin but resistant to erythromycin may harbor inducible erm expression. The double-disk diffusion D-zone test detects this phenotype; a positive result predicts clindamycin failure in vivo and the organism should be reported as clindamycin-resistant. Erm genes are disseminated on plasmids and transposons among streptococci, staphylococci, and enterococci.

The M phenotype of macrolide resistance is mediated by an efflux pump specific to macrolides. Unlike macrolide-lincosamide-streptogramin B resistance, mef-mediated resistance does not confer cross-resistance to clindamycin or streptogramin B because they are not substrates for the mef pump. The M phenotype is particularly prevalent in Streptococcus pneumoniae in North America and produces low-level macrolide resistance. Both erm and mef resistance determinants are common in community Streptococcus pneumoniae isolates, with geographic variation in their relative prevalence.

Macrolide-resistant Mycoplasma pneumoniae has emerged as a significant clinical problem, particularly in Asia, where resistance rates in some series exceed 90% of community-acquired isolates. Resistance arises through mutations in the ribosomal RNA gene at the macrolide binding site. Doxycycline and respiratory fluoroquinolones are the alternatives for macrolide-resistant Mycoplasma pneumoniae in adults. Clinicians should consider this diagnosis in patients with atypical pneumonia not responding to macrolide therapy.